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Abstract: Pancreatic adenocarcinoma carries a dismal prognosis and remains a significant cause 
of cancer morbidity and mortality. Most patients survive less than 1 year; chemotherapeutic 
options prolong life minimally. The best chance for long-term survival is complete resection, 
which offers a 3-year survival of only 15%. Most patients who do undergo resection will go 
on to die of their disease. Research in chemotherapy for metastatic disease has made only 
modest progress and the standard of care remains the purine analog gemcitabine. For resectable 
pancreatic cancer, presumed micrometastases provide the rationale for adjuvant chemotherapy 
and chemoradiation (CRT) to supplement surgical management. Numerous randomized 
control trials, none definitive, of adjuvant chemotherapy and CRT have been conducted and are 
summarized in this review, along with recent developments in how unresectable disease can be 
subcategorized according to the potential for eventual curative resection. This review will also 
emphasize palliative care and discuss some avenues of research that show early promise.
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Introduction
Despite all efforts at developing effective therapy, pancreatic adenocarcinoma carries 
a dismal prognosis1 and remains a significant cause of cancer morbidity and mortality. 
There is no screening test for this disease, and patients are generally only identified 
when already symptomatic with weight loss, back or abdominal pain, or obstructive 
jaundice. Most patients survive less than 1 year; chemotherapeutic options prolong life 
minimally. The best chance for long-term survival is complete resection, which offers 
a 3-year survival of only 15%.2 Most patients who do undergo resection will go on to 
die of their disease3 (see Figure 1). Research in chemotherapy for metastatic disease 
has made only modest progress and the standard of diabetes mellitus care remains the 
purine analog gemcitabine.4
Well-established risk factors for pancreatic cancer include smoking and family his-
tory. There is a slight increased risk with some familial cancer syndromes, including 
Lynch syndrome5 and BRCA2 mutations.6 Recently, obesity has been identified as a 
modifiable risk factor in the development of and mortality from pancreatic cancer.7–10 
There are no screening recommendations for this disease.
In this article, we will review current treatments for pancreatic cancer. We will 
discuss adjuvant therapy and recent developments in how unresectable disease can be 
subcategorized according to the potential for eventual curative resection.   Considering the 
bleak prognosis of this disease, an important challenge is maintaining   quality of remain-
ing life with multidisciplinary support. Therefore, we will emphasize palliative care. OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Finally, we will discuss some avenues of research that show 
early promise as our understanding of the biology of this 
devastating disease improves.
Managing resectable disease
Surgical resection for treatment of localized pancreatic cancer 
is currently the best chance for cure. Unfortunately, up to 
85%11 of patients initially present in advanced or metastatic 
stages, and curative resection is only possible in roughly 13% 
of patients.1 Even in patients who present with more   favorable 
disease and undergo surgery with curative intent, there is a 
high rate of relapse,12,13 with high local recurrence rates of up 
to 50% following surgery alone14 leading to a 5-year survival 
rate of under 5%.1 This aggressive recurrence pattern is highly 
suggestive of the presence of micrometastases at the time of 
surgery.11 For resectable pancreatic cancer, presumed micro-
metastases provide the rationale for adjuvant chemotherapy 
and chemoradiation (CRT) to supplement surgical manage-
ment. Numerous randomized control trials, none definitive, 
of adjuvant chemotherapy and CRT have been conducted, 
summarized in Table 1.
Adjuvant CRT and chemotherapy: 
regional differences
The earliest prospective randomized trial to suggest a survival 
benefit from the addition of postoperative CRT was the Gastro-
Intestinal Study Group (GITSG) trial.15 Patients receiving 
bolus fluorouracil (5-FU) and a split course of 20 Gy radiation 
for 2 cycles after primary surgery followed by maintenance 
Table 1 Randomized control trials of adjuvant chemotherapy and CRT
Study Year Chemo RT No. of 
patients
MOS 2-yr survival 
rate, %
P value
GiTSG Kalser15 1985 5-FURT→5-FU 40 Gy 21 20 42 0.035
Observation 22 11 15
Bakkevold et al119 1993 AMF 30 23 43 0.009
Observation 31 11 32
eORTC Klinkenbijl et al16 1999 5-FURT 60 Gy 60 17.1 37 0.099
Observation 54 12.6 23
eSPAC-1 Neoptolemos et al18 2004 5-FURT 40 Gy 145 15.9 29 0.053
Observation 144 17.9 41
5-FU/Lv 147 20.1 40 0.009
Observation 142 15.5 30
ROTG 9704 Regine et al39 2006 All patients
GeM→5-FURT→GeM 50.4 Gy 221 18.8 0.15
5-FU→5-FURT→5-FU 221 16.9
Pancreas head
GeM→5-FURT→GeM 50.4 Gy 187 20.6 0.033
5-FU→5-FURT→5-FU 194 16.9
Kosuge et al21 2006 5-FU/CDDP 45 12.5 0.94
Observation 44 15.8
CONKO-001 Oettle et al22 2007 GeM 179 22.1 47.5 0.06
Observation 175 20.2 42
Kosuge et al21/Ueno et al23  
(abstract)
2007 GeM 58 22.3 48.3 0.29
Observation 60 18.4 39.8
eSPAC-3 Neoptolemos et al24 2009 5-FU/Lv 551 23.0
GeM 537 23.6
Abbreviations: AMF, adriamycin/mitomycin CRT, chemoradiation; RT, radiation therapy; MOS, median survival overall; GiTSG, Gastrointestinal Tumor Study Group; 
5-FURT, fluorouracil and radiation; CDDP, cisplatin; EORTC, European Organization for Research and Treatment of Cancer; ESPAC, Europen Study Group For Pancreatic 
Cancer; 5-FU, fluorouracil; GEM, gemcitabine; LV, leucovorin; RTOG, Radiation Therapy Oncology Group; CONKO, German Study Group for Pancreatic Cancer.
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Figure 1 Survival of patients with pancreatic cancer categorized by the receipt 
of curative intent surgery. Copyright © 2007. Reproduced with permission from 
Shaib Y, Davila J, Naumann C, ei-Serag H. The impact of curative intent surgery 
on the survival of pancreatic cancer patients: a U.S. Population-based study. Am J 
Gastroenterol. 2007;102(7):1377–1382.OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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5-FU were reported to have a median overall survival (OS) 
of 20 months compared with 11 months with surgery alone. 
Though this study had a small sample size, early termina-
tion, and suboptimal   radiation dosing, it was still highly 
influential, making concurrent adjuvant CRT the standard of 
care in the United States. In Europe, however, the European 
Organization for Research and Treatment of Cancer (EORTC) 
conducted a similar study comparing postoperative radia-
tion with continuous infusion of 5-FU without subsequent 
chemotherapy maintenance. The median duration of survival 
was 19.0 months for the observation group and 24.5 months 
in the treatment group but the study did not reach statistical 
significance (two-tailed test, P = 0.208).16 Thus, CRT did not 
become standard practice in Europe. However, the European 
study may have an inappropriate statistical design that biased 
against the detection of treatment effects. As a follow up to 
the positive GITSG study, a one-tailed rather than two-tailed 
test would have been appropriate and would have brought 
the results to significance (P = 0.049) in favor of CRT.17 This 
finding is even more robust considering that nearly 20% of 
the patients assigned to the CRT arm were not even treated, 
which would further bias the study against CRT.
Despite these criticisms, the debate continued. A sec-
ond line of evidence has led most European clinicians 
to adopt chemotherapy rather than CRT as the current 
standard of care. The Europen Study Group for Pancreatic 
Cancer-1 (ESPAC-1) study showed a near-doubling of benefit 
for adjuvant chemotherapy with infusional 5-FU and leuco-
vorin (LV), but no benefit with 5-FU and radiation. This trial 
had a 2 × 2 factorial design comparing CRT to observation 
and infusional 5-FU/LV to observation. The estimated 5-year 
survival rate was 10% among patients assigned to receive 
CRT and 20% among patients who did not receive CRT 
(P = 0.05).18 However, this study may have suffered from 
selection bias and an insufficient sample size for a 2 × 2 
study design.19 In addition, there was an excessive rate of 
local recurrence in the CRT arm, suggesting the radiation 
schedule was suboptimal.20
Outside the United States, adjuvant 
chemotherapy remains the focus of trials
Trials of adjuvant chemotherapy alone have continued 
subsequent to the EORTC and ESPAC-1 trials. A trial of 
5-FU and cisplatin based in Japan showed no difference, 
and possibly harm in patients receiving this aggressive 
adjuvant chemotherapy regimen.21 The CONKO-001 trial of 
368 patients showed a benefit in disease-free survival (DFS) 
for patients receiving gemcitabine compared with observation 
(median DFS, 13.4 months vs 6.9 months), but only a small 
and insignificant difference in OS.22 A similar but smaller 
study in Japan did not reach statistical significance.23 At 
the 2009 American Society of Clinical Oncology (ASCO) 
annual meeting, Neoptolemos et al24 presented the results 
of ESPAC-3 trial in which patients were randomized 1:1 to 
adjuvant chemotherapy with 5-FU/LV bolus vs gemcitabine. 
The OS was 23.0 months vs 23.6 months (P = 0.39) in this 
large study, with the conclusion that gemcitabine is not supe-
rior to 5-FU in the adjuvant setting.24 However, ESPAC-4, 
currently enrolling in Europe, is based on the assumption 
that gemcitabine is superior to 5-FU in the adjuvant therapy 
setting. ESPAC-4 will directly compare gemcitabine to a 
gemcitabine–capecitabine combination after resection of 
pancreatic cancer, again without radiation. Enrollment of 
more than 1,000 patients is planned. Unfortunately, there 
will be no comparison of adjuvant CRT to chemotherapy 
alone, maintaining the regional differences in both practice 
and clinical trials.
Can locally advanced disease  
be resected?
The most significant advance in treating locally advanced 
disease has been the recognition that treatment has potential 
to downstage tumors to allow secondary surgical manage-
Figure 2 Downstaging with neoadjuvant therapy: 59-year-old man with a 2.2 x 
1.8 cm pancreatic head mass found to be pancreatic adenocarcinoma on biopsy 
A)  Pretreatment  scan.    Note  severe  SMV  impingement,  which  fits  criteria  for 
borderline resectable disease B) Post-treatment scan. The patient was reated with 
neoadjuvant capecitabine 1500 mg po bid and concurrent radiation. The SMv is less 
confined; the pancreas mass remains similar in size. C) Post-operative scan. The 
patient underwent pancreaticoduodenectomy with jugular SMv reconstruction.OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
114
Moss and Lee
ment25 (see Figure 2). With this new paradigm of possibly 
downstaging tumors, locally advanced pancreatic cancer is 
categorized into 2 distinct groups: borderline resectable and 
unresectable, summarized in Table 2.25,26 Before these criteria 
were established, the standard of care for locally advanced 
disease had been concurrent CRT without expectation of 
making the disease resectable.27,28 These criteria allow 
borderline resectable disease with no vascular involvement 
to be distinguished from locally advanced unresectable dis-
ease with vascular involvement. Both these categories may 
  benefit from neoadjuvant therapy, and secondary resection 
has emerged as an important therapeutic goal.
Early  attempts  at  preoperative  treatment  using 
chemotherapy,29 radiotherapy,30 and CRT31 demonstrated 
that neoadjuvant treatment of previously inoperable pan-
creatic tumors may result in potentially curative secondary 
surgery. In this scenario, the chief objective of neoadjuvant 
therapy for borderline resectable patients is to induce a par-
tial tumor response and, therefore, increase the likelihood 
of complete resection with negative margins. Additionally, 
exposure of the tumor to chemotherapeutic agents before 
resection allows for the sensitivity of the tumor to those 
agents to be assessed. Tumors that progress despite therapy 
may be those with aggressive biology that would progress 
even if resected and treated adjuvantly. Those patients who 
progress during neoadjuvant treatment are, therefore, spared 
the morbidity and mortality of major surgery. On the other 
hand, patients with favorable responses to preoperative 
therapy as demonstrated by radiographic tumor regression 
and improvement in serum tumor marker levels may have 
the best chance for an R0 resection and a favorable   long-term 
outcome.25
Might neoadjuvant CRT improve 
resectability and survival?
Preoperative therapy for locally advanced pancreatic cancer 
has been the focus of multiple phase II trials. Several of 
these trials have demonstrated encouraging rates of second-
ary resection.32,33 The emergence of borderline resectable 
disease as a separate category in trials in 2002 (see Table 3) 
has opened the possibility of evaluating the role of neoadju-
vant CRT. Previously, trials failed to distinguish borderline 
resectable from resectable or borderline unresectable disease. 
In the single study to address this subgroup, Brown et al34 
tested a combination of radiosensitizing agents with 50.4 Gy 
of radiation in 13 patients with borderline resectable disease. 
All patients underwent secondary surgery with intent for 
cure. Eighty-five percent (11 patients) had complete, or R0, 
resections, which led to a 2-year survival of 69% (n = 9) and 
8 patients disease-free at 2 years.
In a phase II trial by Massucco et al33 of neoadjuvant 
gemcitabine with 45 Gy radiation in borderline resectable 
and unresectable locally advanced disease, 8 patients who 
had unresectable disease responded favorably to neoad-
juvant therapy and went on to resection. These patients 
had similar OS and DFS to those with initially resectable 
disease receiving the same regimen.33 Like many previous 
trials, this study found margin status to be the most powerful 
predictor of survival. This trial is interesting for having used 
gemcitabine as a radiation sensitizer, albeit at only 50 mg/m2 
twice weekly,33 far less than the full dose of gemcitabine, 
1,000 mg/m2 weekly, that has been shown to be of benefit 
in metastatic disease,4 and which would be hypothesized to 
better treat micrometastases.
Role of gemcitabine in CRT
Historically, 5-FU has been used as a radiation sensitizer in 
pancreatic cancer, even though it has been demonstrated to 
be inferior to gemcitabine for treating metastatic disease.4 
The Massucco et al33 trial, described above demonstrated the 
possibility of secondary surgical resection after CRT, is one 
Table 2 Criteria for defining resectability status25,26
Resectable Borderline 
resectable
Unresectable
venous Patent SMv 
and portal vein
Severe SMv 
impingement or 
reconstructable 
SMv occlusion
Unreconstructable 
SMv/portal 
occlusion  
Greater than 180° 
SMA encasement
Arterial Clear fat plane 
around celiac 
A and SMA
Less than 180° 
abutment of SMA, 
reconstructable 
encasement of SMA
Greater than 180° 
SMA encasement 
Reconstructable 
abutment or 
encasement of 
hepatic artery
Unreconstructable 
SMA involvement
Any celiac 
abutment (head 
mass)
Greater than 180° 
SMA encasement 
(body mass)
Aorta Aortic invasion or 
encasement
Mets No distant 
metastases
Distant 
metastases
Metastases to LN 
beyond field of 
resectionOncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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of a series of trials exploring the potential of gemcitabine 
as a radiation sensitizer. In the Munich Pancreas Trial, 
gemcitabine at a dose of 300 mg/m2 was give on days 1, 
15, and 29 with 5-FU continuous infusion and concurrent 
radiation (45–50 Gy) in 32 patients with locally advanced 
unresectable pancreatic cancer. They demonstrated an 
overall response rate (RR) of 62.5%. An impressive 37.5% 
of patients were found to be resectable after neoadjuvant 
treatment.35
An number of phase I and II trials have explored full-
dose gemcitabine given in conjunction with varying doses 
of radiotherapy36,37 and have shown encouraging RRs, 
allowing in some cases for secondary surgery for previously 
  unresectable disease. In a single-arm trial of 41 patients, 
Small et al38 have reported that full-dose gemcitabine with 
concurrent radiation (36 Gy) in nonmetastatic pancreatic 
cancer resulted in 3 of 9 cases of borderline resectable disease 
going on to secondary resection; 1 of 14 unresectable patients 
went on to resection. The 12-month survival rate in this study 
was 94% (95% confidence interval [CI]: 82%–100%) for 
primarily resectable disease, 76% (95% CI: 47%–100%) 
in secondary resection after neoadjuvant treatment, and 
47% (95% CI: 19%–75%) for unresectable patients. Of 17 
surgically resected patients, 16 showed negative margins at 
the time of resection,36 suggesting that the CRT may have 
contributed to local control; however, the large overlap in 
CIs for these results raises the necessity of a larger scale 
study to confirm the benefit of full-dose gemcitabine with 
concurrent radiation.
Because of the theoretical importance of full-dose gemcit-
abine for treating micrometastatic disease and for improving 
RRs, some researchers argue for the use of gemcitabine before 
and after 5-FU-based CRT in a sandwich regimen, explored in 
the Radiation Therapy Oncology Group (RTOG) 97-04 trial. 
5-FU was used as a radiosensitizer in both groups. Before and 
after CRT, patients received gemcitabine or 5-FU in a 1:1 ratio. 
OS was similar in both groups (18.8 months vs 16.9 months), 
but in subgroup analysis, patients with resectable pancreatic 
head mass had significant benefit on the gemcitabine arm (20.5 
months vs 16.9 months, P = 0.033),39 again suggesting the 
importance of gemcitabine in this disease.
Comparing CRT to chemotherapy: 
neoadjuvant intent
Although there have been no recent trials comparing adjuvant 
chemotherapy to CRT for resected pancreatic cancer, this 
comparison is being made in the setting of locally advanced 
pancreatic cancer.
Eastern Cooperative Oncology Group-4201(ECOG-4201) 
is the first study that directly compared   gemcitabine in combi-
nation with radiation therapy vs gemcitabine alone in patients 
with locally advanced pancreatic cancer. In the radiation arm, 
gemcitabine was given at a dose of 600 mg/m2 weekly concur-
rent with radiation, and then followed by 5 cycles of full-dose 
gemcitabine. The concurrent CRT was found to be more 
myelosuppressive and was also associated with considerable 
gastrointestinal toxicity and fatigue. However, the addition 
of radiation therapy to gemcitabine significantly improved 
OS (P = 0.034) and tripled the survival rate at 24 months for 
patients with locally advanced pancreatic cancer.40
Does more chemotherapy improve RRs 
to radiation?
In a small trial, Marti et al41 found that adding cisplatin 
to gemcitabine with 45 Gy concurrent radiation was well 
tolerated and allowed some patients with locally advanced 
pancreatic cancer to go on to resection. However, this benefit 
has not been borne out in phase III trials. The French 2000–
2001 Fédération Francophone de la Cancéologie Digestive/
Société Française de Radiothérapie Oncologie (FFCD/SFRO) 
study was a phase III trial comparing intensive induction 
CRT (60 Gy, infusional 5-FU and intermittent cisplatin) 
followed by maintenance gemcitabine with gemcitabine 
alone for locally advanced unresectable pancreatic cancer. 
This trial was a departure from the European approach of 
neoadjuvant chemotherapy alone. The intensive regimen 
unfortunately showed a significant decrease in OS from 
13 to 8.6 months,42 possibly associated with toxicity of the 
aggressive chemotherapy. Although RR was not reported, 
there was similar tumor progression in both arms. The role 
of platinum agents in CRT for pancreatic cancer remains 
unsupported by evidence.
who is resectable? radiologic staging
Although computed tomographic (CT) scans are the standard 
imaging modality at present, they are often unable to dif-
ferentiate active pancreatic cancer from necrotic or fibrous 
tissue.43 Therefore, they are ineffective at identifying which 
tumors have been adequately downstaged to allow resection. 
Indeed, there are reports of complete pathologic response to 
neoadjuvant therapy not appreciated on preoperative scans.44 
Thus, an important area of research is the development of 
advanced postprocessing techniques to increase the resolution 
of CT scanning for better restaging of disease,45 an important 
unmet need at present. An alternate modality for clinical 
assessment is 2-deoxy-2-[18F]fluoro-D-glucose-positron OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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emission tomographic scanning, which in 1 small study has 
been used to quantify response to neoadjuvant treatment.46 
One approach to this dilemma is to err on the side of second-
ary surgery for curative intent, but this may increase the rate 
of futile surgery and subsequent complications.
The future of neoadjuvant therapy  
in borderline unresectable  
and resectable diseases
As the above definitions of resectability are incorporated 
into clinical trials and surgical technique and as criteria 
for assessment of margin status become standardized, the 
relative contributions of chemotherapy and radiation to the 
benefit neoadjuvant therapy will become more clear.14 Taken 
together, the trials conducted in locally advanced pancreatic 
cancer suggest that CRT is not only tolerable but also can 
downstage the disease, thus enabling secondary resection, 
possibly prolonging survival. The possibility of using full-
dose gemcitabine as a radiation sensitizer is intriguing, but 
phase III trials have not yet been conducted with full-dose 
gemcitabine as a radiation sensitizer. Until such trials are 
available, a reasonable standard of care for locally advanced 
pancreatic cancer is the RTOG 97-04 sandwich approach with 
full-dose gemcitabine before and after CRT with 5-FU.39
Metastatic disease: treating  
the patient not the disease
Once pancreatic cancer becomes metastatic, it is uniformly 
fatal. At this point, the goal of treatment shifts away from 
curative attempts and toward prolonging survival while main-
taining good quality of life. Chemotherapy is an important 
component of palliative care but must be deployed as part of 
a multidisciplinary approach to treat pain, minimizing weight 
loss, and manage declines in functional status.
Pain control
Pain control in advanced pancreas cancer needs to be aggressive 
and comprehensive. The appropriate initial line of attack is long-
acting narcotics supplemented by short-acting preparations for 
breakthrough pain. A key principle is to balance pain control 
against oversedation in order to maintain both comfortable and 
functional living. For patients who suffer from postprandial 
pain, multidisciplinary support is necessary. Postprandial pain 
may be alleviated by pancreatic enzyme replacement therapy 
(PERT), or celiac plexus block, both detailed below. Nutri-
tional support is also important in staving off cachexia, which 
can interfere with pain management options like transdermal 
fentanyl.
For patients who have localized cancer-related pain, 
often described as band-like and radiating from the epi-
gastrium, an important palliative option is neurolytic celiac 
plexus block (NCPB). In this procedure, an analgesic, such 
as lidocaine and an anti-inflammatory or a neurolytic agent, 
can be introduced to the celiac plexus. At some centers, this 
procedure may be done endoscopically with endoscopic 
ultrasound guidance, but it can also accomplished by 
fluoroscopic and CT guidance (see Figure 3). The approach 
may be made from either an anterior or an posterior 
approach based on anatomy and the patient’s comfort.47 
Celiac plexus block may also be applied intraoperatively 
on initial surgical exploration with 50% ethanol or 6% 
phenol under direct visualization during laparotomy.48 In a 
meta-analysis, partial or complete pain relief was achieved 
in 90% of patients via NCPB.49 NCPB can decrease the 
subsequent onset pain even in patients without preexist-
ing pain at the time of surgery.50 Although the efficacy of 
this procedure is high, the duration or response is limited. 
As patients live longer, the efficacy of repeated NCPB 
diminishes, presumably due to disease   metastasizing past 
the splanchnic bed,47 and systemic   analgesics become 
necessary to control pain.
PeRT
Patients with pancreatic cancer may suffer from symptoms of 
pancreatic enzyme deficiency and malabsorption. The defi-
ciency stems from both disease-related obstruction of the pan-
creatic duct and destruction of normal pancreatic   parenchyma, 
as well as unwanted consequences from interventional or surgi-
cal procedures.51 The rate of malabsorption can be 85%–90% in 
patients with pancreatic carcinoma, even in those who have not 
had surgery.52 Malabsorption can lead to vitamin and mineral 
Figure 3 A) CT image after injection of a small volume of dilute contrast agent 
through  both  needles,  confirming  correct  distribution  of  injected  contrast 
around  the  celiac  axis  (arrows)  prior  to  alcohol  injection.  B)  After  injection 
of alcohol, darkened region (arrow) shows its distribution in the vicinity of the 
celiac plexus. Copyright © 2007. Reproduced with permission from Arellano RS. 
image-guided pain management, Part 1: celiac plexus block for palliative pain relief. 
Radiology Rounds, Vol 5. Boston, MA: Massachusetts General Hospital; 2007.OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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deficiencies, particularly the fat-soluble vitamins A, D, E, and K. 
Symptoms of pancreatic enzyme deficiency include abdominal 
pain and distention, particularly postprandial, flatus, belching, 
diarrhea, steatorrhea, and weight loss.
To avoid symptoms and sequela of these deficiencies, it is 
important to provide pancreatic enzyme replacement therapy 
(PERT). A standard initial dose of replacement therapy is 
50,000 IU of lipase with each meal. The dosage is then 
titrated to symptoms, leading eventually to a widely varying 
therapeutic range. PERT can be optimized with the addition 
of a proton-pump inhibitor, which increases intestinal pH and 
leads to decreased inactivation of prescribed PERT.53
Nutritional status
Pancreatic cancer is associated with cachexia, which is in 
and of itself a significant systemic symptom. Weight loss of 
5% or more has been associated with an increased rate of 
metastatic disease, which renders surgical resection moot.54 
It is not clear whether weight loss is causative since those 
with more tumor burden may lose more weight. Weight loss 
is, therefore, useful as a prognostic indicator55 and has even 
been considered an end point in major trials.4
Cachexia has important implications for symptom man-
agement. Because many cachectic patients with pancreatic 
cancer swallow poorly or have significant nausea and 
vomiting, transdermal fentanyl is an attractive treatment 
option. Unfortunately, cachexia has been demonstrated to 
decrease absorption of the narcotic due to lack of subcuta-
neous fat.56
For patients who have intractable nausea and vomiting 
on the basis of mechanical obstruction not amenable to 
  endoscopic stenting, a gastric bypass surgery may be neces-
sary to allow patients to continue to eat. A   gastrojejunostomy 
with anastomosis between the jejunum and the anterior or 
posterior wall of the stomach can be performed to alleviate 
gastric outlet obstruction.57
Hyperbilirubinemia
Clearance of gemcitabine depends on a functioning liver. 
Thus, biliary tract obstruction due to tumor or complica-
tions of surgery, which may lead to hyperbilirubinemia as 
evidenced by jaundice, pruritus, and even direct neurotoxic-
ity,58 can significantly delay optimal treatment. If the cancer 
is unresectable, biliary obstruction can often be relieved 
endoscopically by the placement of biliary stents.59 Stenting 
can decompress the biliary passages and relieve symptoms 
in the setting of pancreatic cancer, with 60% of patients 
experiencing complete resolution of pain and 25% of patients 
experiencing partial pain relief.59 However, stenting can also 
lead to many infectious complications.60 The main complica-
tion is stent occlusion, which accounts for the risk of cholan-
gitis of approximately 7% in the setting of malignant biliary 
obstruction.61 Biliary stenting is also associated with up to a 
10% postprocedure incidence of cholecystitis.62
To reduce the risk of stent occlusion and subsequent 
infectious complications, plastic stents, if used for malig-
nant biliary obstruction, must be changed regularly. A more 
occlusion-resistant alternative to plastic stents is metal stents, 
which are, therefore, the intervention of choice in patients 
with malignant distal obstructive jaundice due to pancreatic 
carcinoma.63 Plastic stents should only be used in the pallia-
tive setting in patients with short predicted survival, who are 
not expected to require the patency benefits of metal stents. 
Historically, the surgical literature has reported postoperative 
infectious complications associated with preoperative stent-
ing for patients undergoing pancreaticoduodenectomy.64–66 
However, a Cochrane database review found no significant 
increased risk of infectious complications in this group,67 
so there is no known rationale for avoiding this important 
palliative procedure.
In some cases, palliative surgery to bypass the biliary 
obstruction may be possible if endoscopic stenting is not 
feasible. Patency rates appear to be superior with surgical 
as opposed to endoscopic interventions, but at the cost of 
surgical morbidity.63 In addition, patients found to have 
unresectable disease at the time of laparotomy may benefit 
from a surgical biliary bypass with an hepaticojejunostomy, 
a procedure to anastomose the hepatic duct to the jejunum 
to relieve obstruction.57
Chemotherapy for metastatic 
disease
The primary intent of chemotherapy for metastatic pancreatic 
cancer is to relieve symptoms while prolonging survival. 
By causing tumor regression, chemotherapy may relieve 
the symptoms of biliary obstruction, reduce ascites, and 
contribute to resolving pain. Mallinson et al68 published the 
first randomized, controlled trial to demonstrate a survival 
benefit with systemic chemotherapy in 1980. Patients with 
unresectable disease (diagnosed at laparotomy) were treated 
with 5-FU, methotrexate, vincristine, and cyclophosphamide. 
Chemotherapy treatment was associated with a significant 
improvement in OS of 44 weeks compared with only 9 weeks 
with best supportive care (BSC).68 Several other combination 
regimens were then studied with promising results in phase II 
trials, but upon phase III evaluation, resulted in only modest OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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improvements in progression-free survival (PFS) with no 
advantage in OS.69,70 This pattern of improvement in PFS 
without an OS benefit is common in subsequent trials in 
pancreatic cancer as well.
The next advancement in the treatment of metastatic 
disease was the establishment of single-agent gemcitabine 
as standard of care in the late 1990s. Burris et al4 conducted 
the pivotal trial. They compared weekly gemcitabine bolus 
of 1,000 mg/m2 to weekly 5-FU bolus. Due to the pallia-
tive nature of chemotherapy at this stage, a clinical benefit 
response (CBR) scale, a composite score for pain, was used as 
the primary end point. A significant 23.8% of patients receiv-
ing gemcitabine had a CBR vs only 4.8% of patients in the 
5-FU arm with a significant benefit in OS of 5.65 months vs 
4.41 months, with few adverse events associated with the 
gemcitabine chemotherapy.4
Previous efforts to improve on chemotherapy were made 
using 5-FU as the basis for chemotherapy regimens, with little 
success; even a meta-analysis of 5-FU combination regimens 
showed no benefit of 5-FU-based combination therapy compared 
with 5-FU alone.71 For the past several years, researchers have 
been duplicating this experience by adding different chemothera-
pies to a gemcitabine backbone, again with limited success.
efforts to improve upon gemcitabine: 
phase ii promise does not predict  
success in phase iii
Although single-agent gemcitabine demonstrated its superi-
ority over 5-FU in metastatic pancreatic cancer, the benefits 
were still modest.4 A number of trials have tried to improve the 
efficacy of gemcitabine by adding a number of other agents 
(see Table 4). Other efforts have been made to improve the 
efficacy of gemcitabine itself. In phase I studies, gemcitabine 
at a concentration of 20 µmol/L was found to maximize the 
rate of active gemcitabine triphosphate formation. This corre-
lates to a fixed dose rate (FDR) of 10 mg/m2/min.72 A phase II 
trial of FDR gemcitabine was also promising. OS on the FDR 
gemcitabine arm was associated with a significant improve-
ment in OS of 8 months vs 5 months with standard dosing.73 
Despite this encouraging data from a phase II trial, there was 
no benefit observed when FDR gemcitabine was evaluated as 
Table 4 Phase iii studies comparing addition to gemcitabine therapy
Study Chemo Year No. of 
patients
RR, % PFS, mo OS, mo 1-year  
survival, %
e2297 Berlin et al133 GeM 2002 322 5.6 2.2 5.4 14
GeM + 5-FU 6.9 3.4 (P = 0.022) 6.7 (P = 0.09) 20
Reiss et al134 GeM 2005 466 6.2 22
GeM + 5-FU/leuk 5.85 (P = 0.68) 21 (P = 0.68)
Herrmann et al86 GeM 2007 319 7.8 7.2 30
GeM + cap 10.0 8.4 (P = 0.234) 32
Cunningham et al135 GeM 2005 533 7 6.0 19
GeM + cap 14 (P = 0.008) 7.4 (P = 0.26) 26
Heinemann et al136 GeM 2006 190 8.2 3.1 6.0
GeM + cis 10.2 5.3 (P = 0.053) 7.5 (P = 0.15)
e6201 Poplin et al74 GeM 2009 824 6 2.6 4.9 16
FDR GeM 10 (P = 0.11) 3.5 (P = 0.04) 6.2 (P = 0.04) 22
GeM Ox 9 2.7 (P = 0.1) 5.7 (P = 0.22) 21
GeRCOR/GiSCAD GeM 2005 313 17.3 3.7 7.1 27.8
Louvet et al76 GeM Ox 26.8 5.8 (P = 0.04) 9.0 (P = 0.13) 34.7 (P = 0.22)
Rocha Lima et al117 GeM 2004 342 4.4 3.0 6.6 (P = 0.789)
GeM + iri 16.1 (P , 0.001) 3.5 (P = 0.352) 6.3 (P = 0.789) 20
Strathopoulos et al137 GeM 2006 130 10 2.9 6.5 21.8
GeM + iri 15 (P = 0.387) 2.8 6.4 (P = 0.97) 24.3 (P = 0.666)
Abou-Alfa et al138 GeM 2006 349 5.1 3.8 6.2 21
GeM + exa 6.8 3.7 6.7 (P = 0.52) 23 (P = 0.52)
Reni et al139 GeM 2005 104 8.5 3.3 21.3
PeFG 38.5 5.4 (P = 0.0033) 38.5 (P = 0.11)
Oettle et al140 GeM 2005 565 7.1 3.3 6.3 20.1
GeM + pemetrexed 14.8 (P = 0.004) 3.9 (P = 0.11) 6.2 (P = 0.85) 21.4
Abbreviations: RR, response rate; PFS, progression-free survival; OS, overall survival; GEM, gemcitabine; 5-FU, fluorouracil; Leuk, leukemia; cap, capecitabine; cis, cisplatin; 
FDR, fixed dose rate; GERCOR, French Multidisciplinary Clinical Research Group in Oncology; GISCAD, Italian Group for the Study of Gastrointestinal Tract Cancer; 
GeMOx, gemcitabine plus oxaliplatin; iri, irinotecan; exa, exatecan.OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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one of the arms of ECOG-6201, a large phase III trial that also 
looked at the combination of gemcitabine plus oxaliplatin.74 
Although FDR gemcitabine was associated with the longest OS 
(6.2 months), this outcome did not meet criteria for superiority, 
nor did the doublet of gemcitabine with the platinum, another 
area where multiple efforts have been made.
efforts adding a platinum
There has been promising phase II data for adding a platinum to 
gemcitabine. For example, the French Multidisciplinary Clini-
cal Research Group in Oncology (GERCOR) showed promising 
results with oxaliplatin combined with gemcitabine.75 When 
conducted in a phase III trial, however, despite improvements 
in RRs and PFS, OS was not statistically different.74,76 ECOG-
6201, a larger trial, was designed to test 2 promising approaches 
against standard single-agent gemcitabine in 832 patients with 
advanced pancreatic carcinoma. Disappointingly, the addition 
of oxaliplatin increased neither OS nor PFS significantly when 
compared with standard gemcitabine.74 Many authors consider 
this the definitive trial of platinum combinations, although 
interest in the combination continues.
Data presented at 2009 ASCO, including the Gruppo 
Italiano Pancreas-1(GIP-1) trial of gemcitabine combined 
with cisplatin vs gemcitabine alone in locally advanced and 
metastatic pancreatic cancer, failed to demonstrate any OS 
benefit or benefit in RR to adding the platinum.77
Many explanations for this consistent shortcoming among 
phase III trials of gemcitabine with a platinum drug have been 
proposed. Some postulate that this may be due to second-line 
therapy crossovers, or that combination therapy candidates need 
to be carefully selected for good performance status.76,78
Do meta-analyses shed light on the role 
of a platinum analog?
In the metastatic setting, till date, the only first-line phase III 
combination chemotherapy trial to show benefit over single-
agent gemcitabine was the addition of erlotinib.79 Despite 
promising results with the addition of a platinum agent in the 
phase II setting, when conducted in a phase III trial, despite 
improvements in RRs and PFS, OS is not statistically differ-
ent.74,76 A number of meta-analyses have been undertaken in 
an effort to tease out the benefit of combination therapy.80 
Heinemann et al81 pooled the results of the   GERCOR/Ital-
ian Group for the Study of Gastrointestinal Tract Cancer 
(GISCAD) intergroup study comparing gemcitabine plus 
oxaliplatin to gemcitabine and a German multicenter trial 
comparing gemcitabine plus cisplatin vs gemcitabine and 
concluded that a platinum analog significantly improved 
PFS and OS as compared with single-agent gemcitabine 
in advanced pancreatic cancer in patients with a good per-
formance status,81 similar to other pooled analyses.80 These 
meta-analyses raise interesting questions, but are not com-
prehensive enough to dictate standard of care. For example, 2 
phase III trials not included in the Heinemann analysis did not 
show an advantage when cisplatin was combined with gem-
citabine.82,83 Also discouragingly, a different meta-analyses 
showed no significant improvement in survival when using 
cisplatin in combination with gemcitabine.84
efforts adding capecitabine
Another notable example of the difference in results between 
phase II and III trials in pancreatic cancer are trials of capecit-
abine, which shows activity comparable with gemcitabine in 
phase II trials.85 In the phase III setting, however (see Table 4), 
there was no statistically significant difference between the 
gemcitabine plus capecitabine arm compared with the gem-
citabine arm.86 Interestingly, in a post hoc analysis, patients 
in this study with a Karnofsky Performance score (PS) of 
.90 had a significantly improved OS of 10.1 months vs 7.4 
months, suggesting again that the subset of patients with 
excellent PS may benefit from combination therapy.80 The 
positive phase II results may stem in part from better PS in 
phase II trial participants than in larger trials.
Targeting the eGFR pathway: statistical 
significance does not mean  
clinical relevance
Of all molecularly targeted agents studied in phase III trials, 
only erlotinib, targeting the human epidermal growth factor 
receptor 1 (HER-1/EGFR), has demonstrated statistical sig-
nificant improvement over gemcitabine alone. However, the 
clinical benefit of this addition is uninspiring. In a phase III 
randomized trial, erlotinib with gemcitabine was associated 
with statistically significant 1-year survival advantage of 
23% vs 17%; PFS of 3.75 months vs 3.55 months; and OS 
of 6.24 months vs 5.91 months. This was approved by the 
US Food and Drug Administration (FDA) due to all of these 
end points achieving statistical significance, a feat that could 
not be demonstrated in cytotoxic agents above. Clinically, 
however, the addition of erlotinib manifests a median benefit 
of only 0.33 months, or about 10 days.79
The most common toxicity of anti-EGFR agents is an 
acne-like rash, which may vary in severity. Interestingly, in 
a review of both cetuximab and erlotinib in a variety of solid 
tumors, multiple studies demonstrate a correlation between OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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efficacy and severity of the acneiform rash. In a phase II 
study of cetuximab and gemcitabine for pancreatic cancer, 
not only the presence of the rash but also the severity of it 
was associated with longer survival.87
Second-line therapy: an area  
of great need
Currently, there is a lack of proven therapy in the second-
line, a great unmet need as most patients do not have a good 
response to first-line therapy. The only established second-
line regimen after failure of first-line gemcitabine in the 
metastatic setting is 5-FU with oxaliplatin. In the CONKO-
003 trial, a phase III trial of oxaliplatin and 5-FU with folinic 
acid vs BSC, patients who received second-line therapy were 
noted to have an OS of 40 weeks compared with 34.4 weeks 
after initiation of second-line chemotherapy (P = 0.0312).88 
It is notable that in this study, after 46 of 165 patients were 
randomized, the BSC arm was closed due to participating 
centers deciding that BSC alone was no longer acceptable. 
This benefit, although statistically significant, is small and 
points to the dire need for more investigation.
Directions of current research
A number of genetic alterations have been shown to occur 
in pancreatic cancer. Commonly mutated genes include the 
oncogenes K-ras (75%–100%), HER2/neu (about 65%), p16Ink4a 
(.90%), notch1, Akt-2, and COX-2 and also the tumor suppres-
sor genes p53 (45%–75%), DPC4 (approximately 50%), FHIT 
(70%), and BRCA2. Despite this diversity of mutations, none 
of these genes is currently being targeted in clinical practice.89 
The promise of targeted therapies nevertheless continue to hold 
great interest in this disease, and other approaches, such as 
  concentrating the role of the tumor stroma, overcoming resis-
tance mechanisms to chemotherapy, and recruiting immune 
defenses, show early promise and are highlighted below.
Targeted therapies: efforts  
to improve on the best available
The tyrosine kinase inhibitor erlotinib is the first and only 
molecularly targeted therapy approved by the FDA for first-
line treatment of advanced pancreatic cancer in combination 
with gemcitabine.79 As this is currently FDA approved, it is 
discussed above. Several investigators have sought to build 
upon the benefit of erlotinib. A phase I trial was conducted 
of erlotinib CRT with gemcitabine followed by maintenance 
erlotinib for locally advanced pancreatic cancer.90 A retrospec-
tive study of single-agent erlotinib as second-line therapy 
showed no observed responses.91 Second-line erlotinib with 
capecitabine in gemcitabine refractory pancreatic cancer 
showed a modest median survival time of 6.5 months and a 
RR of 10%.92
Cetuximab: limited activity
A monoclonal antibody against HER1/EGFR, cetuximab, has 
been demonstrated to have activity in pancreatic cancer when 
combined with gemcitabine.87 This combination is being tested 
in the phase III setting, but unfortunately, preliminary reports 
suggest that this trial will likely fail to significantly improve OS 
time93 (see Table 5). Nongemcitabine-based first-line therapy 
with cetuximab has also been studied. An ECOG phase II 
trial with randomization between irinotecan and docetaxel 
vs irinotecan and docetaxel plus cetuximab demonstrated 
modest improvements in clinical response with an OS time of 
7.4 months with cetuximab vs 6.5 months without.94
Table 5 Phase iii trials of molecularly targeted agents for advanced and metastatic pancreatic cancer
Author Chemo Year No. of 
patients
RR, % PFS (mo) OS (mo) 1-year 
survival (%)
Bramhall et al141 Marimastat 2001 414 3 2.9 4 14–20
GeM 26 4.9 (P = 0.0001) 5.6 (P = 0.19) 19
Bramhall et al142 GeM 2002 239 16 3.2 5.5 17
GeM + marimastat 11 3.1 (P = 0.68) 5.4 (P = 0.95) 18
Moore et al143 Talomastat 2003 277 1 1.68 3.74 10
GeM 5 3.5 (P , 0.001) 6.59 25
van Cutsem et al144 GeM 2007 688 8 3.6 (P = 0.72) 6.1 24
GeM + tafarnib 6 3.7 6.4 (P = 0.75) 27
Philip93 S0205 Cetuximab 2007 7 3.5 6.5
7 3 (P = 0.058) 6.0 (P = 0.14)
Kindler et al96 
CALGB 8030
Bevacizumab 2007 11 4.7 5.8
10 4.9 (P = 0.99) 6.1 (P = 0.78)
Abbreviations: RR, response rate; PFS, progression-free survival; OS, overall survival; GeM, gemcitabine.OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
122
Moss and Lee
Targeting the vascular epithelial  
growth factor may be inactive  
in pancreatic cancer
The vascular epithelial growth factor (VEGF) and its 
receptors are attractive targets for antineoplastic therapy, 
particularly as they have a theoretical benefit in improving 
chemotherapy delivery to tumor. In a phase II trial, the anti-
VEGF monoclonal antibody bevacizumab demonstrated 
activity in advanced pancreatic cancer with a RR of 21% 
and a median survival time of 8.8 months.95 Yet again, these 
phase II results were not borne out in the phase III setting. The 
Cancer and Leukemia Group B (CALGB) 8030, a phase III, 
trial showed disappointing results for OS and was terminated 
early.96 Sorafenib, a multikinase inhibitor against VEGFR, 
platelet-derived growth factor receptor, Kit, and Flt-3, was 
demonstrated to have no activity in combination with gem-
citabine in phase II trial,97 although it is being investigated 
in the second-line setting.98
Secreted protein acid rich in cysteine 
(SPARC): the stroma as the target
The role of the pancreatic cancer stroma is an area of 
active research regarding the pathogenesis of the dis-
ease and its vigorous resistance to chemotherapy.99,100 
Pancreatic adenocarcinoma is characterized by a strong 
desmoplastic reaction, which may promote the malignant 
phenotype.101,102 Pancreatic stellate cells (PSC) have been 
shown to produce substances that aid in the invasion of 
pancreatic cancer. The level of paracrine secreted protein 
acidic and rich in cysteine (SPARC) from PSC has been 
demonstrated to be inversely proportional to survival.101 
This makes SPARC in the PSCs an attractive adjunct tar-
get. Nab-paclitaxel uses endogenous albumin pathways 
via binding of the albumin to SPARC. In a phase II trial 
as first-line therapy in metastatic pancreatic cancer, nab-
paclitaxel and gemcitabine were given on days 1, 8, and 
15 of a 28-day cycle. One patient had a complete response 
to therapy, 12 patients (24%) had partial response (PR), 
and 20 patients (41%) had stable disease (SD). Median 
PFS increased from 4.8 months for SPARC-negative 
patients to 6.2 months for SPARC-positive patients.103 In 
a proof-of-principle parallel study in mouse xenografts, 
researchers demonstrated that nab-paclitaxel depleted the 
stroma surrounding pancreatic tumors and thus was able to 
facilitate delivery of gemcitabine more effectively. Those 
treated with the combination had a gemcitabine concen-
tration in tumors that was 3.7-fold higher than that seen 
with gemcitabine alone.104 SPARC is, therefore, emerging 
as an important biomarker of response to nab-paclitaxel 
chemotherapy in this disease.
CP-4126: gemcitabine evolved
The human equilibrative nucleoside transporter 1 and 
human concentrative nucleoside transporter 1 and 3 are 
responsible for gemcitabine uptake into tumor cells. Lack 
of these transporters denotes a poorer prognosis with 
adjuvant treatment and predicts for resistance to therapy.105 
A promising new nucleoside analog that bypasses this 
mechanism has shown some benefit in refractory solid 
tumors in phase I trials, including stabilization of disease 
in some patients with pancreatic cancer. Though a deriva-
tive of gemcitabine, CP-4126 does not require nucleoside 
transporters.106 This agent is currently entering phase II 
trials.
vaccine trials: new techniques  
hold promise
In 2002, dendritic cells derived from peripheral blood 
monocytes were transfected with human tumor antigen 
mucin (MUC1) to be used as a vaccine for advanced 
breast, pancreatic, or papillary cancer. In this phase I 
trial, it was demonstrated that immune responses could 
be induced in 4 of 10 patients, but only 1 patient with 
a response had observed benefit. Despite lack of effi-
cacy, treatment was regarded as safe.107 The same year, a 
phase I/II trial using dl1520, a gene-deleted replication-
selective adenovirus that targets malignant cells, was 
delivered by endoscopic ultrasound in combination 
with gemcitabine in locally advanced pancreatic can-
cer. Though this was also deemed safe with only small 
elevations of pancreatic enzymes and no pancreatitis, the 
effect was modest with 20% RR and another 38% SD.108 
One complete remission of liver metastasis of pancre-
atic cancer refractory to gemcitabine was reported.109 
Encouragingly, a recent a phase I trial with peptide vac-
cine for VEGFR2 using the epitope peptide VGFR2-169 
in   combination of gemcitabine shows promising results 
in advanced   pancreatic cancer. The control rate was 67% 
with a OS of 8.7 months with 1 PR and 11 patients (61%) 
with SD.110 Clearly, this is an   evolving field in which 
more study is needed, and   trials are ongoing, including 
a trial of endoscopically-guided intratumoral injections, 
as intratumoral injections have been demonstrated to 
generate an enhanced systemic tumor-specific immune 
response in a preclinical model.111OncoTargets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Summary
Despite improved surgical outcomes and advances in 
  chemotherapy and radiation therapy, overall 5-year survival 
of pancreatic cancer is approximately 5%.112 Although com-
plete surgical resection offers the only chance for long-term 
survival, the majority of patients who undergo surgery with 
curative intent will eventually succumb to the disease.3
A multidisciplinary approach with CRT holds the promise 
of downstaging a locally advanced cancer and sterilizing the 
perivascular neoplastic tissue and even distant micrometa-
static disease and results in a survival advantage as compared 
with unresected patients. Although the optimal regimen 
has not been identified, there is strong phase II evidence 
that full-dose gemcitabine can be tolerated in combination 
with adequate radiation, and this dose is theoretically most 
likely to address micrometastatic disease outside of the 
radiation field. There appears to be a trend toward higher 
RRs with gemcitabine-based CRT that must be confirmed 
in   multicenter trials.38,113–115
In metastatic disease, chemotherapy is an important 
component of a multidisciplinary approach to palliative care, 
which must be supported by pain management and nutrition. 
Gemcitabine has been considered the standard treatment 
for patients with advanced pancreatic cancer ever since 
Burris et al4 demonstrated a modest, yet statistically signifi-
cant, improvement in OS and a significant clinical benefit for 
gemcitabine chemotherapy compared with 5-FU. However, 
  single-agent gemcitabine in multiple trials consistently only 
achieves median OS figures of approximately 6 months, a 
  finding that clearly indicates the need for the development 
of new treatment strategies.116 Phase I and phase II trials of a 
  variety of gemcitabine-based combinations have   demonstrated 
promising activity. Invariably, when these have been   evaluated 
in randomized phase III trials compared with single-agent 
gemcitabine, the results have been disappointing.
The conclusive results of ECOG-6201 establish that a  dding 
oxaliplatin to gemcitabine is not an appropriate standard of 
care for patients with advanced pancreatic cancer.74 Some 
meta-analyses, however, have found that overall RRs were 
significantly improved by gemcitabine-based   combination 
therapy with a platinum80,81 or fluoropyrimidine,80 particularly 
in patients with good performance status. Other combination 
therapies have shown promise in improving the RR, eg, a phase 
III study of the combination of irinotecan with gemcitabine 
vs gemcitabine in patients with advanced or metastatic pan-
creatic cancer, with a primary end point of survival, a statisti-
cally significant improvement in RR was found although the 
primary end point of survival was not reached.117 Similarly, 
the GERCOR trial demonstrated an improved RR with the 
addition of oxaliplatin to gemcitabine,76 a benefit not seen in 
the larger ECOG trial.74
The possibility of improved RR with combination therapy, 
however, does raise the question: would combination therapy 
be worth examining in the neoadjuvant setting, where RR 
dictates the possibility of future resection?
In future trials, it will be important to stratify patients 
by modern criteria for resectability to elucidate the benefit 
of our therapies. Most neoadjuvant trials have grouped 
together: patients with borderline resectable, resectable, and 
borderline unresectable disease. Most chemotherapy trials 
have treated as one group: patients with unresectable locally 
advanced disease, recurrent disease, and metastatic disease. 
There is increasing evidence that the prognosis is different 
in these stages of disease,118 although micrometastasis may 
already present in most patients. We are doing the research 
process and our patients a disservice if we do not stratify the 
patients in our trials by modern criteria. Trials of innovative 
technology, such as vaccines, should pay particular attention 
to the characteristics of patients’ disease.
Some of the most interesting current research seeks 
to differentiate which patients will respond to therapy. As 
evidenced by the relatively low RRs with gemcitabine, bet-
ter biological markers to help predict response are urgently 
needed if we are to make progress in this disease.
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